- Home
- VGI vs JSPR Comparison
VGI vs JSPR Comparison
Compare VGI & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VGI | JSPR |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 68.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VGI | JSPR |
|---|---|---|
| Price | $7.74 | $1.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $25.60 |
| AVG Volume (30 Days) | 46.0K | ★ 3.8M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.68 | $1.39 |
| 52 Week High | $7.99 | $23.11 |
Technical Indicators
Market Signals| Indicator | VGI | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 40.67 | 46.29 |
| Support Level | $7.79 | $1.60 |
| Resistance Level | $7.86 | $1.93 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 37.45 | 36.90 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.